Press Releases

Discovery of highly potent and selective antibody-based GPCR agonists targeting Melanocortin 4 Receptor (MC4R), a key regulator for hunger and satiety, using Confo’s proprietary technology platform Resolution of first-ever structure of a complex between an antibody-based agonist, a GPCR and the G-proteins enabled by Confo’s patent-protected ConfoBody® Cb35 (Nb35) Agonist mimics interaction of the natural […]

Proceeds to support Phase 1 clinical trials for two proprietary programs, and to advance two additional programs to IND approval Company to expand R&D efforts to discover additional development candidates for rare endocrine diseases and obesical Devety, including those targeting Class B GPCRs Portfolio expansion to include a focus on agonistic GPCR antibodies Ghent, Belgium […]

Ghent, Belgium – March 28, 2024 – Confo Therapeutics, a leader in the discovery of novel medicines targeting G-protein coupled receptors (GPCRs), announced today that it has been awarded a EUR 1.6 million grant from Flanders Innovation & Entrepreneurship (VLAIO). The 2-year grant will be used to expand Confo’s ongoing R&D efforts in the discovery of […]

Ghent, Belgium – September 12, 2023 – Confo Therapeutics, a leader in the discovery of novel medicines targeting G-protein coupled receptors (GPCRs), today announced the appointment of Stephen Dowd, PhD, MBA, to its executive team as Chief Business Officer (CBO). “We are thrilled to welcome Stephen to Confo and believe his considerable experience will make him an […]

Ghent, Belgium – August 29, 2023 – Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced the appointment of Dieter Weinand as Independent Chairman of its Board of Directors. Mr. Weinand brings with him a wealth of experience with more than 35 years in the pharmaceutical industry and over 25 years as the […]

Collaboration to make use of Confo’s unique suite of ConfoBody®-enabled antibody discovery technologies on two GPCR targets Confo to receive upfront and milestone payments Tiered royalties payable to Confo on net sales from resulting products Ghent, Belgium – June 15, 2023 – Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors […]

Collaboration to make use of Confo’s unique suite of ConfoBody®-enabled technologies for fragment- and structure-based drug design Confo to receive upfront and milestone payments totaling EUR 168M Tiered royalties payable to Confo on net sales from resulting products Ghent, Belgium – March 30, 2023 – Confo Therapeutics, a leader in the discovery of medicines targeting […]

Confo to receive upfront and milestone payments totaling $630M Company is eligible for up to $590M in additional milestones if Lilly proceeds with a second product candidate Tiered royalties payable to Confo on net sales Confo to have a co-investment option Ghent, Belgium – March 2, 2023 – Confo Therapeutics, a leader in the discovery […]

Ghent, Belgium – October 28, 2022 – Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced that its Scientific Founder and Scientific Advisory Board Chairman, Professor Jan Steyaert, PhD, has been selected as the recipient of the Jacob and Louise Gabbay Award. Each year the award, administered by […]

Ghent, Belgium – September 15, 2022 – Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced that it will present highlights from the preclinical profiling of CFTX-1554, Confo’s lead clinical candidate in neuropathic pain, during the International Association for the Study of Pain (IASP) 2022 World Congress on […]

Ghent, Belgium – June 28, 2022 – Confo Therapeutics announced today that it has been awarded a EUR 1.7 million grant from Flanders Innovation & Entrepreneurship (VLAIO). The award further validates and supports Confo’s leadership in the discovery of novel GPCR (G protein-coupled receptor) drug candidates using its proprietary universal ConfoBody® technology, specifically for the […]

— Confo’s first drug candidate moves into clinical development — Ghent, Belgium – March 10, 2022 – Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced that the first subjects have been dosed in the company’s Phase 1, first-in-human trial of their clinical candidate CFTX-1554, a novel inhibitor […]

Ghent, Belgium, December 15, 2021 – Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced that it has extended its patent estate with four key US and EU patents granted as part of the company’s foundational “Steyaert patents”. The newly added patents (US-11,162,953, US-11,162,954, EP 3557254 and EP […]

— Confo will work together with Regeneron to apply its GPCR drug discovery platform to enable functional antibody discovery — Ghent, Belgium – November 30, 2021 – Confo Therapeutics today announced that it has entered into a collaborative agreement with Regeneron Pharmaceuticals, Inc. whereby Confo’s technology platform, which uses conformationally selective VHH antibodies – ConfoBodies® […]

Confo Therapeutics Establishes Medical Advisory Board Ghent, Belgium – June 10, 2021 – Confo Therapeutics today announced the establishment of its Medical Advisory Board (MAB). The MAB will provide external review and strategic advice for the company’s clinical development program including the future direction of CFTX-1554, Confo’s lead pre-clinical candidate in neuropathic pain. The international […]

Confo Therapeutics Awarded EUR 1M VLAIO Grant for Pre-Clinical Development of CFTX-1554, an AT2R Modulator for the Treatment of Neuropathic Pain Ghent, Belgium – March 30, 2021 – Confo Therapeutics announced today that it has been awarded a EUR 1 million grant from Flanders Innovation & Entrepreneurship (VLAIO). The grant will support the pre-clinical development […]

Confo Therapeutics Announces Selection of First Product Candidate and Initiation of Pre-Clinical Development Ghent, Belgium – October 15, 2020 – Confo Therapeutics today announced the selection of its first preclinical drug candidate, CFTX-1554, a compound designed to address peripheral neuropathic pain with the potential to address additional pain indications. Confo has applied its proprietary, fragment-based […]

Confo Therapeutics Expands Board with Appointment of Rob Scott as Independent Director Ghent, Belgium – June 10, 2020 – Confo Therapeutics today announced the addition of a new member to its Board of Directors with the appointment of Rob Scott, MD, as an Independent Director. Dr. Scott’s career spans 30 years of drug discovery and […]

Confo Therapeutics Appoints Paolo Vicini as Chief Development Officer –New management role underscores Company’s commitment to establishing and advancing its proprietary pipeline of GPCR modulating drug candidates– Ghent, Belgium – June 3, 2020 – Confo Therapeutics today announced the appointment of Paolo Vicini, PhD, MBA, in the newly-created position of Chief Development Officer (CDO) effective […]

Confo Therapeutics to present at Cowen 40th Annual Health Care Conference Ghent, Belgium, 27 February 2020 – Confo Therapeutics, a pioneering biopharma company, today announces that Cedric Ververken, CEO, will present at the Cowen 40th Annual Health Care Conference on Tuesday, March 3, 2020 at 3:00 p.m. ET in Boston, MA. Confo Therapeutics is also […]

Confo Therapeutics reports grant of two key patents for ConfoBodies™ Ghent, Belgium, 2 December 2019 – Confo Therapeutics, a pioneering biopharma company, today announces that it has been granted two key ConfoBody™ patents derived from the patent estate known as the “Steyaert patents”. The Steyaert patents – named after Prof. Jan Steyaert (VIB-VUB), their first-named […]

FierceBiotech names Confo Therapeutics as one of its “Fierce 15” Biotech Companies of 2019 Ghent, Belgium, 23 September 2019 – Confo Therapeutics, a pioneering biopharma company, today announces that it has been named by FierceBiotech as one of 2019’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in […]

Confo Therapeutics and DyNAbind announce drug discovery collaboration to identify novel GPCR-modulating compounds Ghent, Belgium, and Dresden, Germany – 3 July 2019 – Confo Therapeutics, an emerging drug discovery company, and DyNAbind GmbH today announce a drug discovery collaboration on an undisclosed G-protein coupled receptor (GPCR). The collaboration will combine ConfoBody™-enabled GPCRs with DyNAbind’s Dynamic […]

Confo Therapeutics receives €1.7 million grant from VLAIO to progress novel GPCR-modulating compounds for an orphan indication Ghent, Belgium, 20 June 2019 – Confo Therapeutics, an emerging drug discovery company, today announces that it has been awarded a €1.7 million grant from Flanders Innovation & Entrepreneurship (VLAIO). The grant will run over two years and […]

Confo Therapeutics raises €30 million in Series A financing Round led by BioGeneration Ventures and co-led by Wellington Partners, with investments by Fund+, Perceptive Advisors and existing investors Ghent, Belgium, 7 May 2019 – Confo Therapeutics, an emerging drug discovery company, today announces the completion of a €30 million ($33.4 million) Series A financing. The […]

Confo Therapeutics forms Scientific Advisory Board as it accelerates development of proprietary drug discovery engine Ghent, Belgium, 28 February 2019 – Confo Therapeutics, an emerging drug discovery company, today announces the formation of its Scientific Advisory Board (SAB) with four key appointments: Radu Aricescu, Peter Kolb, Graeme Milligan and Jan Steyaert, Founder of Confo Therapeutics, […]

Confo Therapeutics Announces Exclusive, Worldwide License Agreement with VIB for Powerful Novel Structure Determination Technology Licence provides Confo Therapeutics with exclusive access to ‘Megabody’ Technology for High Resolution Cryo-Electron Microscopy evaluation of G-Protein Coupled Receptors, strengthening its drug discovery engine • Confo Therapeutics secures exclusive, worldwide license to new proprietary Megabody technology for GPCRs • […]

Confo Therapeutics Appoints Frank Landolt as its Chief Counsel Legal & Intellectual Property Ghent, Belgium, 6 December 2018 – Confo Therapeutics, an emerging drug discovery company, today announces the appointment of Frank Landolt as its Chief Counsel Legal & IP, effective from 1 January 2019. Frank is joining the Company from Ablynx, now a wholly […]

Confo Therapeutics is awarded a EUR 1M grant to increase its screening capabilities Ghent, Belgium – February 20, 2018 – Confo Therapeutics announced today that it has received a €1 million grant from the Flemish Government through Flanders Innovation & Entrepreneurship (VLAIO). The grant will be used to support the development of new methods for […]

Confo Therapeutics enters into drug discovery collaboration with Roche Ghent, Belgium – December 19, 2017 Confo Therapeutics, an emerging drug discovery company, announced today that it has entered into a research collaboration and license agreement with Roche for the discovery, development and commercialisation of novel, small molecule agonists of an undisclosed G-protein coupled receptor (GPCR) […]

Confo Therapeutics enters into drug discovery collaboration with Lundbeck Ghent, Belgium – September 26, 2017 Confo Therapeutics, an emerging drug discovery company, today announced that it has entered into a drug discovery collaboration with H. Lundbeck A/S, a global pharmaceutical company specializing in psychiatric and neurological disorders. The goal of the collaboration is to deploy […]

Confo Therapeutics is awarded EUR 2.6M in non-dilutive funding for the discovery of new fibrosis treatments and for expanding the use of its unique Confo® technology Ghent, Belgium – February 1, 2017 Confo Therapeutics, an emerging drug discovery company, today announced that it has received a €1.6 million grant from Flanders Innovation & Entrepreneurship (VLAIO). […]

Confo Therapeutics to appoint John Berriman as Chairman of the Board Brussels, December 15, 2016 [09:00 CET] – Confo Therapeutics, an emerging drug discovery company, today announced the appointment of John Edward Berriman as non-executive director and chairman of the board of directors, starting December 21. Commenting on the board appointment, Dr. Cedric Ververken, CEO, […]

Confo Therapeutics appoints Dr. Cedric Ververken as Chief Executive Officer   Brussels, September 7, 2016 [09:00 CET] – Confo Therapeutics, an emerging drug discovery company, announces the appointment of Cedric Ververken as CEO and board member, starting October 1. Dr. Ververken will lead the transition of Confo Therapeutics from a technology company to a drug […]

Confo Therapeutics appoints Dr Christel Menet as Chief Scientific Officer Brussels, May 10, 2016 [09:00 CET] – Confo Therapeutics, an emerging drug discovery company, announced today that Dr Christel Menet is joining the company as Chief Scientific Officer, effective now. Dr. Menet will lead the research activities and build Confo Therapeutics’ pipeline of development programs […]

Confo Therapeutics secures €6.7 million in first financing round Investment will support first-in-class development programs for pathway selective drugs targeting GPCRs Brussels, Tuesday 02 February, 2016 [09:00 GMT] – Confo Therapeutics, an emerging drug discovery company, announced today the completion of its first financing round at €6.7 million. Incorporated in June 2015 by VIB and […]

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close